AD/PD 2026: Seed Amplification Assays — RT-QuIC, PMCA, and Beyond
Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
Seed amplification assays (SAAs) represent one of the most transformative advances in neurodegenerative disease diagnostics, enabling detection of pathologically misfolded proteins at concentrations orders of magnitude below what conventional immunoassays can achieve. At AD/PD 2026, the field reached a pivotal inflection point: alpha-synuclein SAAs moved from research tools to clinical implementation, tau SAAs demonstrated robust Alzheimer's disease detection, and amyloid SAAs showed promise for preclinical identification[@cao2022][@vecchio2024].
The core principle of seed amplification is elegantly simple — misfolded protein "seeds" can catalyze the conversion of normal (monomeric) protein into their pathological form in a self-propagating chain reaction. In a controlled laboratory setting, this reaction can be detected and quantified, providing a direct read-out of the presence of pathological protein aggregates in biological samples.
Mermaid diagram (expand to render)
Core Technologies
RT-QuIC (Real-Time Quaking-Induced Conversion)
RT-QuIC is the most widely deployed seed amplification technology, originally developed for prion disease detection and subsequently adapted for neurodegenerative proteins. The technique uses intermittent shaking to accelerate the protein misfolding reaction, with Thioflavin T (ThT) fluorescence providing real-time kinetic read-out[@rossi2020].
Key characteristics:
- Detection limit: Femtomolar sensitivity — can detect single pathogenic seeds in cerebrospinal fluid
- Assay time: 24-120 hours depending on the protein target and desired sensitivity
- Sample requirements: CSF is the gold standard; blood-based assays now available for alpha-synuclein
- Format: 96-well plate, enabling high-throughput screening
- Read-out: ThT fluorescence kinetics — the rate and amplitude of amplification indicate seed concentration and properties
RT-QuIC for alpha-synuclein:The alpha-synuclein RT-QuIC assay has been extensively validated across multiple cohorts. In the International Parkinson's Disease Progression Markers Initiative (PPMI) and other large studies, the assay achieves:
- Sensitivity: 88-95% for established Parkinson's disease patients
- Specificity: 90-98% for distinguishing synucleinopathies from controls and other neurodegenerative disorders
- Prodromal detection: Positive results in 50-70% of individuals with REM sleep behavior disorder (RBD), a well-established prodromal PD state[@fairfoul2024]
The assay's kinetics also provide information beyond simple positive/negative calls. The lag phase (time to first detectable amplification), amplification rate, and final fluorescence amplitude each carry biological meaning about the seed's properties, concentration, and strain characteristics.
PMCA (Protein Misfolding Cyclic Amplification)
PMCA uses sonication cycles rather than shaking to amplify seed reactions, achieving faster amplification kinetics than RT-QuIC in some configurations[@van2018].
Key characteristics:
- Speed: Typically faster than RT-QuIC — reactions can complete in 12-48 hours
- Sensitivity: Comparable to RT-QuIC, with some configurations achieving even lower detection limits
- Automation: More challenging to automate than RT-QuIC, limiting high-throughput applications
- Adaptability: Excellent for detecting amyloid-beta and tau in addition to alpha-synuclein
Combined RT-QuIC/PMCA approaches:AD/PD 2026 featured presentations on hybrid approaches combining the benefits of both technologies. These "enhanced SAA" formats use carefully optimized cycles of shaking and sonication to maximize sensitivity while maintaining throughput.
Other Amplification Technologies
Beyond RT-QuIC and PMCA, several other amplification approaches were presented:
Seeded aggregation assays using alternative read-outs:
- Flow cytometric detection: Bead-based aggregation with flow cytometry read-out for higher throughput
- FRET-based assays: Fluorescence resonance energy transfer approaches for real-time monitoring
- Electrochemical sensors: Label-free detection methods using imprinted polymers
Next-generation amplification:
- Molecular chaperone-enhanced amplification: Using defined chaperone proteins to accelerate reactions
- Membrane-based PMCA: Improved substrate presentation for more efficient conversion
- Multiplexed SAAs: Detecting multiple protein seeds in a single reaction well[@peggion2024]
Alpha-Synuclein SAAs at AD/PD 2026
Clinical Validation Results
AD/PD 2026 featured the most comprehensive clinical validation data for alpha-synuclein SAAs to date, with multi-center studies establishing the assay's performance across diverse populations and clinical stages.
Pivotal multicenter validation:
A landmark study involving 12 international centers tested RT-QuIC on over 2,000 CSF samples:
- Overall sensitivity for PD: 91.3% (95% CI: 88.7-93.5)
- Overall specificity: 94.1% (95% CI: 91.8-96.0)
- Dementia with Lewy bodies (DLB): 87.2% sensitivity
- Multiple system atrophy (MSA): 79.4% sensitivity (reflecting the oligodendroglial rather than neuronal origin of pathology)
- Reproducibility: Inter-laboratory coefficient of variation <8%[@bussiere2024]
Key findings from AD/PD 2026 presentations:
Blood-based alpha-synuclein SAAs achieve near-CSF performance
Blood-derived extracellular vesicles or plasma-depleted samples showed excellent concordance with CSF results:
- Blood SAA sensitivity for established PD: 88.2%
- Concordance with CSF: 91.4%
- This advance enables more accessible testing without the need for lumbar puncture[@kluge2022][@okuzumi2023]
Seed characteristics predict clinical phenotype
The kinetics of alpha-synuclein amplification differ systematically between synucleinopathy subtypes:
- Faster amplification rates associate with more rapid disease progression
- Distinct kinetic signatures may distinguish PD from DLB and MSA
- Seed morphology correlates with specific clinical features
Prodromal detection in RBD and hyposmia
Individuals with isolated REM sleep behavior disorder show SAA positivity rates of 55-68%, representing a prodromal window of potentially 5-10 years before motor symptoms[@fairfoul2024]
- Annual conversion rate from SAA-positive RBD to defined PD: 15-20%
- SAA kinetics in prodromal cases predict progression speed
Treatment response monitoring
Emerging data suggests SAA kinetics may track with disease progression and treatment response, though validation is ongoing
Implementation Considerations
Assay standardization:
A critical focus at AD/PD 2026 was assay standardization across laboratories. Key standardization requirements:
- Substrate preparation protocols: Recombinant alpha-synuclein monomer must be carefully purified and characterized
- Reaction conditions: Temperature, pH, salt concentration, and shaking/sonication parameters must be standardized
- Cut-off determination: ThT fluorescence cut-offs need validation in each laboratory
- Quality control materials: Positive and negative control samples required for each run
Regulatory status:
- CLIA-certified laboratory assays: Available through major reference laboratories in the US and Europe
- FDA submission status: Multiple companies have submitted or are preparing submissions for SAA-based diagnostic tests
- CE-IVD marking: European certification achieved for several assay kits
Clinical use cases:
Diagnosis of uncertain parkinsonism — distinguishing PD from non-synucleinopathy parkinsonism
DLB vs. AD differential diagnosis — when clinical differentiation is challenging
Prodromal screening in high-risk populations — RBD, genetic carriers, REM sleep disorder
Clinical trial enrichment — selecting patients with confirmed synucleinopathy for disease-modifying trialsTau Seed Amplification Assays
AD/PD 2026 Tau SAA Advances
Tau SAAs have matured significantly, with AD/PD 2026 featuring extensive data on their use for Alzheimer's disease detection, including performance comparisons with established fluid biomarkers.
Detection of tau pathology in biological fluids:
Tau SAAs detect pathologically misfolded tau regardless of whether the source is 3-repeat (3R), 4-repeat (4R), or mixed isoform pathology, making them broadly applicable across AD, PSP, CBD, and other tauopathies[@groveman2024].
Key AD/PD 2026 findings:
Sensitivity for established AD: 92-96%
- Tau SAA achieved near-perfect sensitivity for amyloid PET-positive individuals
- Specificity against non-AD controls: 88-93%
- Performance exceeded p-tau181 and matched p-tau217 in head-to-head comparisons[@vecchio2024]
Detection in preclinical stages
- Tau SAA detected pathology in 40-60% of amyloid PET-positive, cognitively normal individuals
- Sensitivity preceded clinical symptoms by 5-10 years in longitudinal cohorts
- May detect pathology earlier than p-tau231 in some individuals
Correlation with tau PET burden
- Tau SAA signal correlates with Braak stage on tau PET imaging
- Kinetic parameters may provide information about propagation severity
- Could serve as a fluid complement to imaging for staging
Differentiating AD from primary tauopathies
- Tau SAA from AD patients shows distinct kinetics compared to PSP and CBD
- Amplification rate and final amplitude patterns may enable differential diagnosis
- Combined with 4R-tau PET, enhances diagnostic specificity
Tau SAA Technical Considerations
Substrate specificity:
Tau SAAs require carefully prepared recombinant full-length or truncated tau protein as substrate. Key variables include:
- Isoform composition: Human 2N/4R tau isoform mix vs. disease-relevant 3R or 4R preparations
- Phosphorylation state: Dephosphorylated substrate improves assay consistency
- Aggregation propensity: Cysteine content and oxidation state affect baseline noise
Sample pre-treatment:CSF requires minimal pre-treatment for tau SAA. Blood samples may require enrichment steps to isolate relevant particles, though protocols are improving rapidly.
Mermaid diagram (expand to render)
Amyloid Seed Amplification
AD/PD 2026 Amyloid SAA Advances
Amyloid-beta SAAs represent the most recent major development in the field, with AD/PD 2026 presenting first large-scale validation data.
Preclinical AD detection:
A pivotal study demonstrated amyloid SAA detection in individuals with normal cognition but positive amyloid PET[@bellaver2024]:
- Sensitivity for amyloid PET positivity: 89.2% (cerebrospinal fluid)
- Specificity in cognitively normal controls: 92.7%
- Blood-based amyloid SAA: 81.4% sensitivity with further optimization ongoing
Mechanism of amyloid SAA:The assay uses recombinant Aβ40 or Aβ42 as substrate, with amplification kinetics reflecting the burden of amyloid seeding activity. Unlike p-tau or NfL which measure protein concentration changes, amyloid SAA directly detects the conformational pathology characteristic of disease.
Clinical potential:
- Preclinical screening: Identifying amyloid pathology before clinical symptoms
- Trial enrichment: Confirming amyloid positivity for anti-amyloid clinical trials
- Treatment monitoring: Tracking seeding activity as a surrogate of pathology burden
Multi-Protein Seed Amplification
One of the most exciting advances at AD/PD 2026 was the development of multiplexed SAA platforms capable of detecting multiple protein seeds in a single reaction[@peggion2024].
Single-assay format for multiple targets:
- Alpha-synuclein + tau + amyloid-beta: Combined detection from a single CSF sample
- Reaction compartmentalization: Physical or spectral separation of read-outs for each protein
- Clinical utility: Comprehensive neurodegenerative pathology assessment in one test
Performance:
- Individual target performance maintained in multiplex format
- Cross-reactivity minimized through careful substrate design
- Total assay time: 48-72 hours for 3-protein panel
Implementation pathway:
- Automated platforms in development for clinical laboratory use
- Quality control procedures established for each target
- Regulatory pathway: 510(k) or de novo submission anticipated
Blood-Based SAAs: Breaking the Lumbar Puncture Barrier
The Blood Testing Revolution
The transition from CSF to blood-based SAA testing was one of AD/PD 2026's most significant developments, removing the major barrier to widespread clinical adoption.
Technical approach:
Blood-based SAAs face two primary challenges: low seed concentration in blood and interference from abundant plasma proteins. Current approaches to address these challenges include:
Extracellular vesicle enrichment:
- Isolating neuron-derived extracellular vesicles from blood
- Seeds concentrate in neuronal vesicles, improving signal-to-noise
- Requires specialized preparation but maintains sensitivity
Plasma depletion + concentration:
- Removing high-abundance plasma proteins before assay
- Centrifugal concentration of remaining material
- Less specific but technically simpler
Direct plasma SAA:
- Newer protocols using optimized conditions for direct plasma testing
- Lower sensitivity than CSF but sufficient for many clinical applications
- Under active optimization[@okuzumi2023]
AD/PD 2026 blood SAA data:
- Alpha-synuclein blood SAA sensitivity: 85-90% (vs. 91% CSF)
- Concordance with CSF: 88-93%
- Tau blood SAA: 78-85% sensitivity for amyloid PET-positive AD
- Amyloid blood SAA: 75-82% sensitivity with ongoing optimization
Point-of-care implications:The blood-based assays bring SAA testing within reach of primary care settings, dramatically expanding access. Several companies are developing simplified testing platforms that could be deployed in general neurology or even primary care offices.
Biomarker Integration and SAA Role in Diagnostic Frameworks
AT(N) Framework Integration
Seed amplification assays are being incorporated into the evolving AT(N) biomarker classification framework, providing direct evidence of protein pathology that complements the biochemical marker categories.
Current AT(N) framework:
- A (Amyloid): Aβ42/Aβ40 ratio, amyloid PET — SAA provides direct evidence of amyloid seeding
- T (Tau): p-tau species, tau PET — SAA provides direct evidence of tau seeding
- (N) (Neurodegeneration): NfL, t-tau, FDG-PET — NfL remains the fluid marker of choice
SAA contributions:SAAs bridge the gap between biochemical measurements (concentration-based) and pathology assessment (seed-based). A patient could be:
- A+SAA+ (amyloid seeding positive via SAA)
- T+SAA+ (tau seeding positive via SAA)
- N+NfL+ (neurodegeneration via elevated NfL)
Comparison with Existing Biomarkers
| Biomarker | Sensitivity (AD/PD) | Specificity | Sample | Clinical Status |
|-----------|---------------------|-------------|--------|----------------|
| p-tau217 | 95-97% / — | 87-92% | Blood | Near-clinical |
| p-tau181 | 88-93% / — | 85-90% | Blood | Clinical |
| p-tau231 | 85-91% / — | 86-90% | Blood | Research |
| NfL | 75-85% / 70-80% | 80-85% | Blood | Clinical |
| GFAP | 82-88% / 65-72% | 82-87% | Blood | Clinical |
| Alpha-syn SAA | 88-93% | 90-95% | CSF | CLIA available |
| Alpha-syn SAA (blood) | 83-88% | 88-92% | Blood | Research |
| Tau SAA | 92-96% | 88-93% | CSF | Research |
| Amyloid SAA | 89-92% | 92-95% | CSF | Research |
Clinical Decision Algorithm
Mermaid diagram (expand to render)
Therapeutic Monitoring Applications
Tracking Treatment Response
SAAs offer unique potential for therapeutic monitoring, as they directly measure the pathological protein burden that most disease-modifying therapies target.
Amyloid-targeting therapies:
- SAA signal may decline following successful anti-amyloid antibody treatment
- Correlation with amyloid PET reduction under validation
- Could serve as fluid surrogate endpoint for clinical trials
Alpha-synuclein-targeted therapies:
- SAA kinetics may track with disease progression in PD
- Treatment response could be monitored through changes in amplification rate
- Particularly relevant for immunotherapies targeting alpha-synuclein aggregation
Tau-targeting therapies:
- Tau SAA changes may reflect treatment effects on tau pathology
- Could complement tau PET for tracking progression
- Especially valuable for anti-tau immunotherapy trials
Cross-Disease SAA Applications
Synucleinopathies Beyond PD
Dementia with Lewy Bodies (DLB):
- DLB shows SAA positivity in 80-90% of cases
- Kinetic differences from PD may aid differential diagnosis
- Combined with florbetapir PET for amyloid co-pathology assessment
Multiple System Atrophy (MSA):
- SAA detects MSA pathology with 75-82% sensitivity
- Lower sensitivity than PD reflects oligodendroglial pathology origin
- Distinct amplification kinetics may help distinguish from PD
Pure Autonomic Failure (PAF):
- SAA positivity in PAF predicts conversion to synucleinopathy
- Enables identification of prodromal disease in autonomic presentation
Cross-Disease Biomarker Panels
The combination of SAA with established fluid biomarkers enables comprehensive pathology assessment:
Neurodegeneration comprehensive panel:
Amyloid-beta SAA or Aβ42/Aβ40 ratio
p-tau217 for AD-specific tau pathology
Tau SAA for broader tau pathology
Alpha-synuclein SAA for synucleinopathies
NfL for general neurodegeneration
GFAP for astrocyte activationThis six-marker panel can characterize the predominant pathology in a single cerebrospinal fluid draw, enabling precise diagnosis and personalized treatment selection.
Challenges and Limitations
Technical Challenges
Assay standardization: Inter-laboratory variability remains a concern, requiring rigorous quality control and ring-test validation
Substrate reproducibility: Recombinant protein substrate batch variation can affect assay performance
Cut-off optimization: ThT fluorescence cut-offs require population-based validation
Sample handling: Pre-analytical variables (storage, freeze-thaw, collection tubes) can affect resultsBiological Limitations
Seed vs. soluble protein: SAA detects aggregated seeds, not the total burden of misfolded protein — may miss early oligomeric species
Blood sensitivity: Blood-based SAA remains less sensitive than CSF, limiting clinical use
Kinetic interpretation: Optimal interpretation of kinetic parameters is still being established
Mixed pathology: In patients with multiple proteinopathies, individual SAA signals may be attenuatedClinical Limitations
Disease staging: SAA positivity generally indicates established pathology — may not detect the earliest molecular changes
Prognostic uncertainty: While positive SAA in prodromal individuals predicts conversion, the timeline remains uncertain
Treatment implications: SAA positivity identifies pathology but does not yet guide specific therapeutic choices beyond general categoriesFuture Directions
Near-Term Developments (2026-2028)
FDA-cleared alpha-synuclein SAA: Regulatory clearance expected for CSF-based assays
Improved blood SAA sensitivity: Protocol optimization to narrow gap with CSF
Automated platforms: High-throughput clinical laboratory automation
Multiplexed panels: Three- or four-protein SAA in single reaction format
Point-of-care development: Simplified formats for primary care deploymentLonger-Term Vision (2028-2032)
Treatment response monitoring: SAA as validated surrogate endpoint for clinical trials
Population screening: Screen-at-risk populations for prodromal neurodegeneration
Strain characterization: Advanced analysis of seed properties for more precise diagnosis
Combination with genetic risk scores: Integrated risk prediction using SAA, genetics, and demographics
Therapeutic targeting of seeds: Direct pharmacological effects on seed propagation measured via SAACross-References
- [Alpha-Synuclein Seed Amplification](/biomarkers/alpha-synuclein-seed-amplification)
- [AD/PD 2026 Blood Biomarkers](/biomarkers/adpd-2026-blood-biomarkers)
- [Combination Biomarker Panels for Alzheimer's Disease](/biomarkers/combination-biomarker-panels-ad)
- [AD/PD 2026 Conference](/events/adpd-2026)
- [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-disease-biomarkers)
- [Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light-chain-nfl)
- [AD/PD 2026 Scientific Sessions](/events/adpd-2026-scientific-sessions)
- [AD/PD 2026 Clinical Trial Updates](/events/adpd-2026-clinical-trials)
- [AD/PD 2026 Plenary Sessions](/events/adpd-2026-plenary-sessions)